

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1. (withdrawn) A method of treating a condition associated with ocular neovascularization in a subject comprising administration of a peptide comprising the amino acid sequence of SEQ ID NO: 1.
2. (withdrawn) A method of treating a condition associated with ocular neovascularization in a subject comprising administration of a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.
3. (withdrawn) The method of claims 1 or 2, wherein said ocular neovascularization is choroidal neovascularization.
4. (withdrawn) The method of claim 3, wherein said condition is age-related macular degeneration (AMD) or high myopia.
5. (withdrawn) The method of claims 1 or 2, wherein said ocular neovascularization is retinal neovascularization.
6. (withdrawn) The method of claim 5, wherein said condition is diabetic retinopathy, retinopathy of prematurity, or central vein occlusion.
7. (withdrawn) The method of claims 1 or 2, wherein said ocular neovascularization is iris neovascularization.
8. (withdrawn) The method of claim 7, wherein said condition is neovascular glaucoma.

9. (withdrawn) The method of claims 1 or 2, wherein said peptide further comprises a modification.
10. (withdrawn) The method of claim 9, wherein said modification is selected from the group consisting of addition of an antibody Fc and pegylation.
11. (withdrawn) The method of claims 1 or 2, wherein said peptide comprises one or more D form amino acids.
12. (withdrawn) The method of claim 1 or 2, wherein said peptide contains an N-terminal amide.
13. (withdrawn) A method of treating cancer in a subject comprising administration of a peptide comprising the amino acid sequence of SEQ ID NO: 1.
14. (withdrawn) A method of treating cancer in a subject comprising administration of a peptide with an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, and SEQ ID NO: 5.
15. (withdrawn) The method of claims 13 or 14, wherein said cancer is breast cancer.
16. (withdrawn) The method of claims 13 or 14, wherein said peptide further comprises a modification.
17. (withdrawn) The method of claim 16, wherein said modification is selected from the group consisting of addition of an antibody Fc and pegylation.
18. (withdrawn) The method of claims 13 or 14, wherein said peptide comprises one or more D form amino acids.

19. (withdrawn) The method of claim 13 or 14, wherein said peptide contains an N-terminal amide.
20. (currently amended) A pharmaceutical composition comprising a peptide comprising the amino acid sequence of designated as SEQ ID NO: 1.
21. (currently amended) A pharmaceutical composition comprising a peptide with comprising an amino acid sequence ~~selected from the group consisting of~~ designated as SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, ~~and or~~ SEQ ID NO: 5.
22. (currently amended) The pharmaceutical composition of ~~claims 20 or 21~~ claim 20 or claim 21, wherein ~~said the~~ the peptide further comprises a modification selected from pegylation, biotinylation, acetylation, ubiquitination, amidation, a radiolabel, an Fc antibody, and one or more D form amino acids.
23. (currently amended) The pharmaceutical composition of claim 22, wherein ~~said the~~ the peptide is modified by ~~modification is selected from the group consisting of~~ addition of an Fc antibody ~~and or by~~ pegylation.
24. (currently amended) The pharmaceutical composition of ~~claims 20 or 21~~ claim 22, wherein ~~said the~~ the peptide comprises one or more D form amino acids.
25. (currently amended) The pharmaceutical composition of ~~claims 20 or 21~~ claim 22, wherein ~~said the~~ the peptide ~~contains~~ comprises an N-terminal amide.
26. (currently amended) A kit ~~for the treatment of a condition associated with ocular neovascularization in a subject~~ comprising (a) a composition comprising a peptide comprising ~~the an~~ amino acid sequence of designated as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5 and (b) instructions for administration of ~~said the~~ the composition.

27-29. (canceled)

30. (new) The kit of claim 26, wherein the peptide further comprises a modification selected from pegylation, biotinylation, acetylation, ubiquitination, amidation, a radiolabel, an Fc antibody, and one or more D form amino acids.

31. (new) The kit of claim 30, wherein the peptide is modified by addition of an Fc antibody or by pegylation.

32. (new) The kit of claim 30, wherein the peptide comprises one or more D form amino acids.

33. (new) The kit of claim 30, wherein the peptide comprises an N-terminal amide.

34. (new) The kit of claim 26, wherein the peptide comprises the amino acid sequence designated as SEQ ID NO: 1.

35. (new) The kit of claim 26, wherein the peptide comprises the amino acid sequence designated as SEQ ID NO: 2.

36. (new) The kit of claim 26, wherein the peptide comprises the amino acid sequence designated as SEQ ID NO: 3.

37. (new) The kit of claim 26, wherein the peptide comprises the amino acid sequence designated as SEQ ID NO: 4.

38. (new) The kit of claim 26, wherein the peptide comprises the amino acid sequence designated as SEQ ID NO: 5.

39. (new) The composition of claim 21, wherein the peptide comprises the amino acid sequence designated as SEQ ID NO: 2.
40. (new) The composition of claim 21, wherein the peptide comprises the amino acid sequence designated as SEQ ID NO: 3.
41. (new) The composition of claim 21, wherein the peptide comprises the amino acid sequence designated as SEQ ID NO: 4.
42. (new) The composition of claim 21, wherein the peptide comprises the amino acid sequence designated as SEQ ID NO: 5.